Looking Back On Our Third Year

Today, we celebrate our third anniversary since launching on January 27, 2015! This third year has been our most exciting yet, and we’re reflecting back on each highlight and accomplishment.

Believe Ball

In early February 2017, Emily made a special announcement, unveiling our plans to host the first Emily Whitehead Foundation Believe Ball — an event that had been on our dream board since our founding. With the help of a team of dedicated volunteers, we spent the following months planning every detail of the gala, including the theme: Write A Better Story.

This inspired a new campaign that coincided with our mission to Activate The Cure. With the Believe Ball, our goal became to Write A Better Story for children fighting cancer, a story that results in patients receiving more targeted and less toxic treatments, such as CAR-T cell therapy.

On October 28, 2017, our dream became reality when CAR-T cell therapy patients, their families, the doctors and researchers who worked to develop the treatment, and Foundation supporters all joined us for an evening that can only be described as magical. The event was the largest gathering of patients treated with CAR-T cell therapy to date and raised $450,000!

[Read: Inaugural Emily Whitehead Foundation Believe Ball Raises $450,000]

5 Years Cancer Free

While the month of May is special each year, May 2017 held extra significance. After turning 12 years old at the start of the month, Emily celebrated 5 years cancer free on May 10, 2017 — a milestone anniversary, often considered the threshold for being declared cured.

[Read: Celebrating 5 Years Cancer Free!]

FDA Approval of CAR-T

On July 12, 2017, we traveled to Washington D.C. to attend the FDA’s Oncologic Drugs Advisory Committee hearing for Novartis’s CAR-T cell treatment CTL019 for children with relapsed/refractory acute lymphoblastic leukemia—the very treatment that Emily was the first to receive in the clinical trial at Children’s Hospital of Philadelphia just five years prior. Tom was selected to speak before the advisory committee and advocate for the treatment’s approval, an honor he shared with fellow CAR-T parents Don McMahon and Amy Kappen. Moments after Tom spoke, the committee put the decision to a vote: 10-0, unanimously in favor of the pending approval.

[Read: FDA Advisory Committee Unanimously Votes ‘YES’ to Pending Approval of CAR-T Cell Therapy CTL019]

On August 30, 2017, the decision to approve the treatment was confirmed and CTL019 (now Kymriah) became the first gene cell therapy to be approved by the U.S. FDA — also a milestone achievement for pediatric cancer, as one of only three instances where a treatment was approved for children before adults.

[Read: FDA Approves CAR-T Cell Treatment for Pediatric Patients with Acute Lymphoblastic Leukemia]

 

Other notable highlights:

Thank you also to the following events for inviting us to attend:

NYC Hope Gala, AACR Annual Meeting, Immuno-Oncology Summit, Atlantic Live: Children & Cancer, Washington Post: Chasing Cancer

 

Thank you to all who contributed to making our third year such a success. We look forward to entering our fourth year by continuing to advocate for better treatment options for children with cancer, following our missions to Activate The Cure and Write A Better Story!

By | 2018-02-01T17:11:53+00:00 January 27th, 2018|News and Updates|0 Comments

Leave a Reply